ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD

In today’s episode, we had the pleasure of speaking with Sarah Rutherford, MD, about the evolving role of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) testing for lymphoma treatment decision-making. Dr Rutherford is an associate professor of clinical medicine in the Division of Hematology/Oncology at Weill Cornell Medicine in New York, New York. 

In our exclusive interview, Dr Rutherford discussed the usefulness of ctDNA for guiding patient treatment, clinical trials that are ongoing to determine the best use of this type of assay, how personalized ctDNA testing offers the potential for disease surveillance and effective intervention, key hurdles in the way of widespread implementation of ctDNA testing in clinical practice, and how integration with next-generation sequencing is expected to further tailor treatment strategies.